Your browser doesn't support javascript.
loading
Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2).
Habeshian, Talar S; Peeri, Noah C; De Vivo, Immaculata; Schouten, Leo J; Shu, Xiao-Ou; Cote, Michele L; Bertrand, Kimberly A; Chen, Yu; Clarke, Megan A; Clendenen, Tess V; Cook, Linda S; Costas, Laura; Dal Maso, Luigino; Freudenheim, Jo L; Friedenreich, Christine M; Gallagher, Grace; Gierach, Gretchen L; Goodman, Marc T; Jordan, Susan J; La Vecchia, Carlo; Lacey, James V; Levi, Fabio; Liao, Linda M; Lipworth, Loren; Lu, Lingeng; Matias-Guiu, Xavier; Moysich, Kirsten B; Mutter, George L; Na, Renhua; Naduparambil, Jeffin; Negri, Eva; O'Connell, Kelli; O'Mara, Tracy A; Onieva Hernández, Irene; Palmer, Julie R; Parazzini, Fabio; Patel, Alpa V; Penney, Kathryn L; Prizment, Anna E; Ricceri, Fulvio; Risch, Harvey A; Sacerdote, Carlotta; Sandin, Sven; Stolzenberg-Solomon, Rachael Z; van den Brandt, Piet A; Webb, Penelope M; Wentzensen, Nicolas; Wijayabahu, Akemi T; Wilkens, Lynne R; Xu, Wanghong.
Afiliação
  • Habeshian TS; Department of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.
  • Peeri NC; Department of Research and Evaluation, Division of Health Services Research and Implementation Science, Kaiser Permanente Southern California, Pasadena, California.
  • De Vivo I; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schouten LJ; Department of Epidemiology, Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts.
  • Shu XO; Medicine, Harvard Medical School, Boston, Massachusetts.
  • Cote ML; Department of Epidemiology, GROW-Research Institute for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Bertrand KA; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Chen Y; Fairbanks School of Public Health, Department of Epidemiology, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana.
  • Clarke MA; Slone Epidemiology Center, Boston University, Boston, Massachusetts.
  • Clendenen TV; Population Health, New York University School of Medicine, New York, New York.
  • Cook LS; Division of Cancer Epidemiology and Genetics, NCI, Rockville, Maryland.
  • Costas L; Population Health, New York University School of Medicine, New York, New York.
  • Dal Maso L; Epidemiology, Colorado School of Public Health, Aurora, Colorado.
  • Freudenheim JL; Cancer Epidemiology Research Programme, Institut Català d'Oncologia, Barcelona, Spain.
  • Friedenreich CM; Consortium for Biomedical Research in Epidemiology and Public Health - CIBERESP, Carlos III Institute of Health, Madrid, Spain.
  • Gallagher G; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Gierach GL; Department of Epidemiology and Environmental Health, University at Buffalo, State University of New York, Buffalo, New York.
  • Goodman MT; Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada.
  • Jordan SJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • La Vecchia C; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Lacey JV; Cancer Prevention and Control Program, Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Levi F; School of Public Health, University of Queensland, Herston, Queensland, Australia.
  • Liao LM; Department of Clinical Medicine and Community Health, University of Milan, Milan, Italy.
  • Lipworth L; Department of Computational and Quantitative Medicine, City of Hope, Duarte, California.
  • Lu L; Epidemiology and Health Services Research, University of Lausanne, Lausanne, Switzerland.
  • Matias-Guiu X; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Moysich KB; Department of Medicine, Vanderbilt University, Nashville, Tennessee.
  • Mutter GL; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.
  • Na R; Department of Pathology, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
  • Naduparambil J; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Negri E; Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • O'Connell K; Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • O'Mara TA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Onieva Hernández I; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Palmer JR; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Parazzini F; Cancer Research Program, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Patel AV; Faculty of Medicine, Cancer Epidemiology Research Programme and University of Barcelona, Institut Català d'Oncologia, Barcelona, Spain.
  • Penney KL; Slone Epidemiology Center and Department of Medicine, Boston University, Boston, Massachusetts.
  • Prizment AE; Department of Clinical Medicine and Community Health, University of Milan, Milan, Italy.
  • Ricceri F; Population Science, American Cancer Society, Kennesaw, Georgia.
  • Risch HA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Sacerdote C; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
  • Sandin S; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota.
  • Stolzenberg-Solomon RZ; Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
  • van den Brandt PA; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.
  • Webb PM; Unit of Cancer Epidemiology, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Turin, Italy.
  • Wentzensen N; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
  • Wijayabahu AT; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Wilkens LR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Xu W; Epidemiology, Maastricht University, Maastricht, the Netherlands.
Cancer Epidemiol Biomarkers Prev ; 33(6): 788-795, 2024 Jun 03.
Article em En | MEDLINE | ID: mdl-38530242
ABSTRACT

BACKGROUND:

The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors.

METHODS:

We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors.

RESULTS:

Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09-1.19). There was significant heterogeneity by study design (Phet < 0.01), with a stronger magnitude of association observed among case-control versus cohort studies. Stronger associations were also noted for pre-/perimenopausal women and never users of postmenopausal hormone therapy.

CONCLUSIONS:

Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. IMPACT This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Hipertensão Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Hipertensão Idioma: En Ano de publicação: 2024 Tipo de documento: Article